MabThera SC for subcutaneous formulation
E822403
MabThera SC for subcutaneous formulation is a subcutaneously administered version of the monoclonal antibody rituximab, used primarily in the treatment of certain blood cancers and autoimmune diseases.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| MabThera SC | 0 |
Statements (25)
| Predicate | Object |
|---|---|
| instanceOf |
pharmaceutical drug
ⓘ
rituximab-containing medicinal product ⓘ subcutaneous formulation ⓘ |
| administrationSite | subcutaneous tissue ⓘ |
| belongsToRegimen | rituximab-based chemotherapy regimens ⓘ |
| brandOf | MabThera NERFINISHED ⓘ |
| drugClass | monoclonal antibody ⓘ |
| hasActiveIngredient | rituximab NERFINISHED ⓘ |
| hasDosageForm | solution for injection ⓘ |
| indication |
certain autoimmune disorders
ⓘ
chronic lymphocytic leukemia ⓘ non-Hodgkin lymphoma NERFINISHED ⓘ |
| isBiologic | true ⓘ |
| isBrandNameOf | rituximab subcutaneous formulation ⓘ |
| isFormulationOf | rituximab NERFINISHED ⓘ |
| isParenteral | true ⓘ |
| isSubcutaneousVersionOf | intravenous rituximab ⓘ |
| mechanismOfAction | B-cell depletion ⓘ |
| pharmacologicalClass | anti-CD20 monoclonal antibody ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| target | CD20 antigen NERFINISHED ⓘ |
| therapeuticArea |
immunology
ⓘ
oncology ⓘ |
| usedFor |
treatment of certain autoimmune diseases
ⓘ
treatment of certain blood cancers ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.